102 related articles for article (PubMed ID: 7611182)
1. Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas.
Holden JA; Perkins SL; Snow GW; Kjeldsberg CR
Am J Clin Pathol; 1995 Jul; 104(1):54-9. PubMed ID: 7611182
[TBL] [Abstract][Full Text] [Related]
2. Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas.
Bauman ME; Holden JA; Brown KA; Harker WG; Perkins SL
Mod Pathol; 1997 Mar; 10(3):168-75. PubMed ID: 9071722
[TBL] [Abstract][Full Text] [Related]
3. MIB1 (Ki-67) expression in non-Hodgkin's lymphomas.
Kalogeraki A; Tzardi M; Panagiotides I; Koutsoubi K; Bolioti S; Rontogianni D; Stefanaki K; Zois E; Karidi E; Darivianaki K; Delides G; Kanavaros P
Anticancer Res; 1997; 17(1A):487-91. PubMed ID: 9066700
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival.
Holden JA; Townsend JJ
Mod Pathol; 1999 Dec; 12(12):1094-100. PubMed ID: 10619260
[TBL] [Abstract][Full Text] [Related]
5. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
Holden JA
Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease.
Brown MS; Holden JA; Rahn MP; Perkins SL
Am J Clin Pathol; 1998 Jan; 109(1):39-44. PubMed ID: 9426516
[TBL] [Abstract][Full Text] [Related]
7. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer.
Lynch BJ; Guinee DG; Holden JA
Hum Pathol; 1997 Oct; 28(10):1180-8. PubMed ID: 9343325
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate.
Willman JH; Holden JA
Prostate; 2000 Mar; 42(4):280-6. PubMed ID: 10679757
[TBL] [Abstract][Full Text] [Related]
9. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen.
Kreipe H; Wacker HH; Heidebrecht HJ; Haas K; Hauberg M; Tiemann M; Parwaresch R
Am J Pathol; 1993 Jun; 142(6):1689-94. PubMed ID: 7685150
[TBL] [Abstract][Full Text] [Related]
10. Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas.
Coleman LW; Perkins SL; Bronstein IB; Holden JA
Hum Pathol; 2000 Jun; 31(6):728-33. PubMed ID: 10872667
[TBL] [Abstract][Full Text] [Related]
11. Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: correlation with working formulation and Kiel classification in formalin-fixed paraffin-embedded material.
Rabenhorst SH; Burini RC; Schmitt FC
Pathology; 1996 Jan; 28(1):12-6. PubMed ID: 8714262
[TBL] [Abstract][Full Text] [Related]
12. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Staley BE; Samowitz WS; Bronstein IB; Holden JA
Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas.
Taniguchi K; Wakabayashi T; Yoshida T; Mizuno M; Yoshikawa K; Kikuchi A; Nakashima N; Yoshida J
J Neurosurg; 1999 Sep; 91(3):477-82. PubMed ID: 10470824
[TBL] [Abstract][Full Text] [Related]
14. Human DNA topoisomerase II-alpha.
Martinchick J; Rahn M; Jolles C; Holden J
Int J Oncol; 1997 Jun; 10(6):1229-34. PubMed ID: 21533509
[TBL] [Abstract][Full Text] [Related]
15. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas.
Pich A; Ponti R; Valente G; Chiusa L; Geuna M; Novero D; Palestro G
J Clin Pathol; 1994 Jan; 47(1):18-22. PubMed ID: 7907607
[TBL] [Abstract][Full Text] [Related]
16. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression.
Monnin KA; Bronstein IB; Gaffney DK; Holden JA
Hum Pathol; 1999 Apr; 30(4):384-91. PubMed ID: 10208458
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome.
Schrader C; Meusers P; Brittinger G; Teymoortash A; Siebmann JU; Janssen D; Parwaresch R; Tiemann M
Leukemia; 2004 Jul; 18(7):1200-6. PubMed ID: 15116121
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of cellular proliferative activity in 35 T-cell non-Hodgkin's lymphomas. Use of proliferating cell nuclear antigen and Ki-67 (MIB-1) antibodies and nucleolar organizer regions.
Caulet-Maugendre S; Patey M; Granier E; Joundi A; Gentile A; Caulet T
Anal Quant Cytol Histol; 1996 Oct; 18(5):337-44. PubMed ID: 8908304
[TBL] [Abstract][Full Text] [Related]
20. Biological heterogeneity of diffuse mixed small and large cell non-Hodgkin's lymphomas assessed by DNA flow cytometry and Ki67.
Palestro G; Pich A; Chiusa L; Geuna M; Ponti R; Kerim S; Novero D; Valente G
Leuk Lymphoma; 1995 Nov; 19(5-6):467-72. PubMed ID: 8590848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
